Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic Review
- PMID: 38255174
- PMCID: PMC10813081
- DOI: 10.3390/biomedicines12010067
Hemoadsorption Therapy for Critically Ill Patients with Acute Liver Dysfunction: A Meta-Analysis and Systematic Review
Abstract
Critically ill patients are at risk of developing acute liver dysfunction as part of multiorgan failure sequelae. Clearing the blood from toxic liver-related metabolites and cytokines could prevent further organ damage. Despite the increasing use of hemoadsorption for this purpose, evidence of its efficacy is lacking. Therefore, we conducted this systematic review and meta-analysis to assess the evidence on clinical outcomes following hemoadsorption therapy. A systematic search conducted in six electronic databases (PROSPERO registration: CRD42022286213) yielded 30 eligible publications between 2011 and 2023, reporting the use of hemoadsorption for a total of 335 patients presenting with liver dysfunction related to acute critical illness. Of those, 26 are case presentations (n = 84), 3 are observational studies (n = 142), and 1 is a registry analysis (n = 109). Analysis of data from individual cases showed a significant reduction in levels of aspartate transaminase (p = 0.03) and vasopressor need (p = 0.03) and a tendency to lower levels of total bilirubin, alanine transaminase, C-reactive protein, and creatinine. Pooled data showed a significant reduction in total bilirubin (mean difference of -4.79 mg/dL (95% CI: -6.25; -3.33), p = 0.002). The use of hemoadsorption for critically ill patients with acute liver dysfunction or failure seems to be safe and yields a trend towards improved liver function after therapy, but more high-quality evidence is crucially needed.
Keywords: critical care; database meta-analysis; hemoadsorption; liver dysfunction.
Conflict of interest statement
Z.M. is a full-time employee of CytoSorbents Europe GmbH. The other authors state that they have no conflicts of interest.
Figures




Similar articles
-
Cytokine Hemoadsorption as Rescue Therapy for Critically Ill Patients With SARS-CoV-2 Pneumonia With Severe Respiratory Failure and Hypercytokinemia.Front Med (Lausanne). 2022 Jan 10;8:779038. doi: 10.3389/fmed.2021.779038. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35083241 Free PMC article.
-
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry.Crit Care. 2023 Jun 19;27(1):243. doi: 10.1186/s13054-023-04517-3. Crit Care. 2023. PMID: 37337243 Free PMC article.
-
Beta-blocker treatment in the critically ill: a systematic review and meta-analysis.Ann Med. 2022 Dec;54(1):1994-2010. doi: 10.1080/07853890.2022.2098376. Ann Med. 2022. PMID: 35838226 Free PMC article.
-
Hemoadsorption in 'Liver Indication'-Analysis of 109 Patients' Data from the CytoSorb International Registry.J Clin Med. 2021 Nov 5;10(21):5182. doi: 10.3390/jcm10215182. J Clin Med. 2021. PMID: 34768702 Free PMC article.
-
Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.Front Immunol. 2023 Feb 3;14:1074465. doi: 10.3389/fimmu.2023.1074465. eCollection 2023. Front Immunol. 2023. PMID: 36817416 Free PMC article. Review.
Cited by
-
Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios.J Clin Med. 2024 May 12;13(10):2853. doi: 10.3390/jcm13102853. J Clin Med. 2024. PMID: 38792395 Free PMC article.
-
Comment on Gaspari et al. Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios. J. Clin. Med. 2024, 13, 2853.J Clin Med. 2025 Jan 23;14(3):716. doi: 10.3390/jcm14030716. J Clin Med. 2025. PMID: 39941387 Free PMC article.
-
Reply to Riva et al. Comment on "Gaspari et al. Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios. J. Clin. Med. 2024, 13, 2853".J Clin Med. 2025 Jan 27;14(3):822. doi: 10.3390/jcm14030822. J Clin Med. 2025. PMID: 39941493 Free PMC article.
-
Potential Clinical Use of CytoSorb® for Ticagrelor and Rivaroxaban Elimination Prior to Emergency Orthopedic Surgery in Trauma Patients.Life (Basel). 2025 Jul 3;15(7):1065. doi: 10.3390/life15071065. Life (Basel). 2025. PMID: 40724567 Free PMC article.
-
Artificial liver support with Cytosorb and continuous veno-venous hemodiafiltration versus advanced organ support (ADVOS) for critically ill patients with hyperbilirubinemia and acute-on-chronic liver failure (ACLF).BMC Nephrol. 2025 Aug 4;26(1):432. doi: 10.1186/s12882-025-04342-6. BMC Nephrol. 2025. PMID: 40759919 Free PMC article.
References
-
- Kanjo A., Ocskay K., Gede N., Kiss S., Szakács Z., Párniczky A., Mitzner S., Stange J., Hegyi P., Molnár Z. Efficacy and safety of liver support devices in acute and hyperacute liver failure: A systematic review and network meta-analysis. Sci. Rep. 2021;11:4189. doi: 10.1038/s41598-021-83292-z. - DOI - PMC - PubMed
-
- Bingold T.M., Lefering R., Zacharowski K., Meybohm P., Waydhas C., Rosenberger P., Scheller B., Care Registry Group Individual Organ Failure and Concomitant Risk of Mortality Differs According to the Type of Admission to ICU—A Retrospective Study of SOFA Score of 23,795 Patients. PLoS ONE. 2015;10:e0134329. doi: 10.1371/journal.pone.0134329. - DOI - PMC - PubMed
-
- Kramer L., Jordan B., Druml W., Bauer P., Metnitz P., DEAA for the Austrian Epidemiologic Study on Intensive Care. ASDI Study Group Incidence and prognosis of early hepatic dysfunction in critically ill patients—A prospective multicenter study. Crit. Care Med. 2007;35:1099-e7. doi: 10.1097/01.CCM.0000259462.97164.A0. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials